 AMAG Pharmaceuticals, Inc. AMAG today announced it has completed the sale of its rights to Intrarosa prasterone to Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group in 2018 that specializes in womens health and menopause-related conditions, for up to 125 million, including upfront fixed consideration of 20 million and contingent, sales-based milestone payments of up to 105 million. As mentioned in our first quarter earnings release, the sale of Intrarosa is an important step in our strategic evolution, said Scott Myers AMAGs president and chief executive officer. 